Literature DB >> 18682893

Low-grade gliomas in older patients: a retrospective analysis of prognostic factors.

Nader Pouratian1, Melike Mut, Jay Jagannathan, M Beatriz Lopes, Mark E Shaffrey, David Schiff.   

Abstract

Low-grade gliomas (LGG) are increasingly being diagnosed in older patients (>or=60 years). The rising incidence is incompletely understood but demands an analysis of the natural history and prognostic factors to determine if there are differences compared to younger populations. We retrospectively review a consecutive series of 20 older patients who presented between 1991 and 2004 with LGG to characterize the presentation, management, outcomes, and prognostic factors in older patients with LGG. Median follow-up was 27.3 months. Thirty-five percent of patients harboured oligodendrogliomas. Patients presented in equal numbers with seizure, focal neurological deficit, and mental status change. Median overall survival (OS) was 27.3 months. Patients who survive beyond 2 years experience prolonged periods of progression-free survival. Younger age, seizure presentation, and radiation treatment were prognostic of OS on multivariate analysis. Similarities with previous reports of LGG suggest that age should not affect the management of LGG patients. Prospective studies of older patients with LGG are needed to further characterize the optimum management of these patients.

Entities:  

Mesh:

Year:  2008        PMID: 18682893     DOI: 10.1007/s11060-008-9669-3

Source DB:  PubMed          Journal:  J Neurooncol        ISSN: 0167-594X            Impact factor:   4.130


  42 in total

1.  Supratentorial low grade astrocytoma: prognostic factors, dedifferentiation, and the issue of early versus late surgery.

Authors:  M L van Veelen; C J Avezaat; J M Kros; W van Putten; C Vecht
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-05       Impact factor: 10.154

Review 2.  Molecular pathogenesis of oligodendroglial tumors.

Authors:  Judith W M Jeuken; Andreas von Deimling; Pieter Wesseling
Journal:  J Neurooncol       Date:  2004-11       Impact factor: 4.130

3.  Trends in incidence of brain and central nervous system tumors in Norway, 1970-1999.

Authors:  T B Johannesen; E Angell-Andersen; S Tretli; F Langmark; K Lote
Journal:  Neuroepidemiology       Date:  2004 May-Jun       Impact factor: 3.282

4.  Low-grade cerebral astrocytomas. Survival and quality of life after radiation therapy.

Authors:  C A North; R B North; J A Epstein; S Piantadosi; M D Wharam
Journal:  Cancer       Date:  1990-07-01       Impact factor: 6.860

5.  Regional heterogeneity in the proliferative activity of human gliomas as measured by the Ki-67 labeling index.

Authors:  S W Coons; P C Johnson
Journal:  J Neuropathol Exp Neurol       Date:  1993-11       Impact factor: 3.685

6.  A prospective study on glioblastoma in the elderly.

Authors:  Alba A Brandes; Francesca Vastola; Umberto Basso; Franco Berti; Giampietro Pinna; Antonino Rotilio; Marina Gardiman; Renato Scienza; Silvio Monfardini; Mario Ermani
Journal:  Cancer       Date:  2003-02-01       Impact factor: 6.860

7.  Low-grade astrocytomas: treatment results and prognostic variables.

Authors:  C A Medbery; K L Straus; S M Steinberg; J D Cotelingam; W S Fisher
Journal:  Int J Radiat Oncol Biol Phys       Date:  1988-10       Impact factor: 7.038

8.  Prognostic implications of p53 overexpression in supratentorial astrocytic tumors.

Authors:  B S Chozick; J C Pezzullo; M H Epstein; P W Finch
Journal:  Neurosurgery       Date:  1994-11       Impact factor: 4.654

9.  Supratentorial low-grade astrocytoma. Correlation of computed tomography findings with effect of radiation therapy and prognostic variables.

Authors:  Y Shibamoto; Y Kitakabu; M Takahashi; J Yamashita; Y Oda; H Kikuchi; M Abe
Journal:  Cancer       Date:  1993-07-01       Impact factor: 6.860

10.  Incidence trends of adult primary intracerebral tumors in four Nordic countries.

Authors:  Stefan Lönn; Lars Klaeboe; Per Hall; Tiit Mathiesen; Anssi Auvinen; Helle C Christensen; Christoffer Johansen; Tiina Salminen; Tore Tynes; Maria Feychting
Journal:  Int J Cancer       Date:  2004-01-20       Impact factor: 7.396

View more
  9 in total

Review 1.  Update on molecular findings, management and outcome in low-grade gliomas.

Authors:  T David Bourne; David Schiff
Journal:  Nat Rev Neurol       Date:  2010-11-02       Impact factor: 42.937

Review 2.  Management of elderly patients with gliomas.

Authors:  Jaime Gállego Pérez-Larraya; Jean-Yves Delattre
Journal:  Oncologist       Date:  2014-10-23

3.  Prognosis of older patients with low-grade glioma: A retrospective study.

Authors:  Priya Kumthekar; Vaibhav Patel; Carly Bridge; Alfred Rademaker; Irene Helenowski; Maciej M Mrugala; Jason K Rockhill; Sean Grimm; Kristin R Swanson; Jeffrey Raizer
Journal:  Integr Cancer Sci Ther       Date:  2017-10-23

4.  Identification and Validation of a Seizure-Free-Related Gene Signature for Predicting Poor Prognosis in Lower-Grade Gliomas.

Authors:  Jinxing Li; Jing Huan; Fu Yang; Haixin Chen; Mingguang Wang; Xueyuan Heng
Journal:  Int J Gen Med       Date:  2021-10-29

Review 5.  Management of low-grade glioma.

Authors:  Nader Pouratian; David Schiff
Journal:  Curr Neurol Neurosci Rep       Date:  2010-05       Impact factor: 5.081

Review 6.  Low-grade gliomas.

Authors:  Jimmy Ruiz; Glenn J Lesser
Journal:  Curr Treat Options Oncol       Date:  2009-04-19

7.  Prognosis and patterns of care in elderly patients with glioma.

Authors:  Fabio M Iwamoto; Anne S Reiner; Lakshmi Nayak; Katherine S Panageas; Elena B Elkin; Lauren E Abrey
Journal:  Cancer       Date:  2009-12-01       Impact factor: 6.860

8.  Low-grade gliomas in older patients: long-term follow-up from Mayo Clinic.

Authors:  David A Schomas; Nadia N Laack; Paul D Brown
Journal:  Cancer       Date:  2009-09-01       Impact factor: 6.860

9.  Molecular features and clinical outcomes in surgically treated low-grade diffuse gliomas in patients over the age of 60.

Authors:  Ramin A Morshed; Seunggu J Han; Shawn L Hervey-Jumper; Melike Pekmezci; Irene Troncon; Susan M Chang; Nicholas A Butowski; Mitchel S Berger
Journal:  J Neurooncol       Date:  2018-11-29       Impact factor: 4.506

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.